Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler on Lung Function in Subjects With COPD and a Low PIFR

Trial Profile

A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler on Lung Function in Subjects With COPD and a Low PIFR

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Revefenacin (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 11 Oct 2018 According to a Theravance Biopharma media release, data from this study were presented at the 2018 CHEST annual meeting.
    • 11 Oct 2018 Results presented in a Theravance Biopharma media release.
    • 08 Oct 2018 According to a Theravance Biopharma media release, data will be presented at at the 2018 CHEST annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top